# Ipamorelin vs Tesamorelin: Comparing Two Growth Hormone Secretagogues

> Ipamorelin vs Tesamorelin: two distinct GH-axis peptides compared by receptor class, mechanism, FDA approval status, and body composition findings across the published research record.

## Mechanism Comparison: Ipamorelin vs Tesamorelin

Tesamorelin is a 44-amino-acid synthetic GHRH analog that binds the GHRH receptor (GHRH-R) via Gαs/adenylate cyclase/cAMP pathway [13]. Tesamorelin does not engage GHS-R1a.

Ipamorelin binds GHS-R1a via Gq/11/PLC/Ca²⁺, triggering direct acute GH vesicle exocytosis and suppressing hypothalamic somatostatin [1]. The two compounds enter the GH-axis from different receptor families, activating different intracellular cascades on the same somatotroph cell [13, 14].

## Regulatory Status: FDA-Approved vs Research-Only

Tesamorelin received FDA approval in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy [13]. It is the only FDA-approved GH-axis secretagogue for any human indication.

Ipamorelin has not received FDA approval for any indication. The Phase 2 clinical trial (NCT00672074) did not result in an NDA submission [15]. The FDA PCAC voted against 503A compounding inclusion in October 2024 [16].

## Body Composition Data: Tesamorelin vs Ipamorelin

Tesamorelin reduced visceral adipose tissue approximately 15% at 26 weeks and approximately 18% at 52 weeks in HIV lipodystrophy patients [13]. A 2026 meta-analysis confirmed selective visceral (not subcutaneous) fat reduction with acceptable safety at 26–52 weeks [17]. A 2023 post-hoc analysis found consistent visceral fat reduction with minimal adverse metabolic events [18].

Ipamorelin's body composition data is preclinical and heterogeneous. Bone studies show lean mass accretion and body weight gain [3, 4]. The Lall 2001 mouse study showed fat pad weight increase via GH-independent mechanisms [8]. The Sinha 2020 review acknowledged paucity of human clinical data [12]. No visceral fat reduction study directly paralleling the tesamorelin trials exists for ipamorelin in humans.

## Is Tesamorelin Better Than Ipamorelin?

Tesamorelin has an FDA-approved indication, a large controlled clinical trial base, and validated visceral fat reduction data [13, 17, 18]. Ipamorelin has preclinical selectivity, bone, and GI motility data and one incomplete Phase 2 clinical trial record [1, 3, 4, 5, 15]. The compounds have not been tested head-to-head on a shared endpoint in humans. No direct superiority comparison is supported by the published record.

## References

[1] Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
[3] Johansen PB, et al. Ipamorelin induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113.
[4] Andersen NB, et al. Ipamorelin counteracts glucocorticoid-induced decrease in bone formation. Growth Horm IGF Res. 2001;11(5):266-272.
[5] Venkova K, et al. Efficacy of ipamorelin in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-1116.
[8] Lall S, et al. GH-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001;280(1):132-138.
[12] Sinha DK, et al. Beyond the androgen receptor: GH secretagogues in body composition management. Transl Androl Urol. 2020;9(Suppl 2):S149-S159.
[13] Dhillon S. Spotlight on tesamorelin in HIV-associated lipodystrophy. BioDrugs. 2011;25(5):337-338.
[14] Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37.
[15] Helsinn Therapeutics. NCT00672074. ClinicalTrials.gov. 2017.
[16] FDA Pharmacy Compounding Advisory Committee. Briefing document. 2024.
[17] Meta-analysis of tesamorelin RCTs. Diabetes Res Clin Pract. 2026;222:112113.
[18] Post hoc analysis of Phase III tesamorelin data. PMC. 2023.

---

A grid-indexed literature digest on Ipamorelin — nineteen primary findings, clean GH pulses, and no commercial position on any of them.